According to Elara Capital’s Domestic Liquidity Tracker, the changes in pharma and tech were led by HDFC MF, ICICI Prudential MF, and SBI Mutual Fund.

Cipla shares broke out above ₹1,580–₹1,590 on strong volumes, with technical indicators signaling further gains.

Sensex and Nifty traded higher on Thursday, driven by realty and oil & gas stocks, extending their five-day rally on optimism ...

Nifty Pharma index closed up 0.95% at 22177.7 today. The index is down 1.00% over last one month. Among the constituents, Mankind Pharma Ltd gained 3.73%, Cipla Ltd jumped 3.02% and Dr Reddys ...

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration ...

At 11:30 am on Thursday, Dr Reddys Labs stock was among the top gainers on the Nifty 50. Dr Reddys Labs was trading at Rs 1,266.20, a 1.67% increase from its previous close. Cipla ...

CHENNAI: Indian equity markets ended Thursday’s session with modest gains, supported by financials and Reliance Industries, ...

An update from Theravance Biopharma ( ($TBPH) ) is now available. On August 15, 2025, Theravance Biopharma and Mylan entered into a Settlement ...

Investors are increasingly turning to ‘safer’ MNC pharma stocks with a domestic focus at a time when the Trump administration ...